Old Bridge, NJ, United States of America

Riza Bibiano

This inventor holds 1 USPTO granted patent. Top assignee: Nymox Pharmaceutical Corporation. Active years: 2007.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Riza Bibiano: Innovator in Neural Thread Protein Research

Introduction

Riza Bibiano is an accomplished inventor based in Old Bridge, NJ (US). He has made significant contributions to the field of biotechnology, particularly in the area of neural thread proteins. His innovative work has led to the development of a patent that holds promise for diagnostic and therapeutic applications.

Latest Patents

Riza Bibiano holds a patent for "Preferred segments of neural thread protein." This invention is directed to preferred repeat sequences of Neural Thread Protein (NTP), peptides, mimetics, antibodies, and nucleic acids of the preferred sequences. The patent also encompasses diagnostic and therapeutic methods utilizing these preferred NTP sequences. This work highlights the potential of NTP in advancing medical science.

Career Highlights

Riza is currently associated with Nymox Pharmaceutical Corporation, where he continues to explore the applications of his research. His dedication to innovation in the pharmaceutical industry has positioned him as a key figure in the development of new therapeutic strategies.

Collaborations

Riza collaborates with notable colleagues, including Judith Fitzpatrick and Paul A Averback. These partnerships enhance the research environment and contribute to the advancement of their collective goals in biotechnology.

Conclusion

Riza Bibiano's work in neural thread proteins exemplifies the impact of innovative research in the medical field. His contributions through patents and collaborations are paving the way for future advancements in diagnostics and therapeutics.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…